Potent cooperation between the NUP98-NSD1 fusion and FLT3-ITD mutation in acute myeloid leukemia induction

by Angeliki Thanasopoulou, Alexandar Tzankov, and Juerg Schwaller

Haematologica 2014 [Epub ahead of print]

Citation: Thanasopoulou A, Tzankov A, and Schwaller J. Potent cooperation between the NUP98-NSD1 fusion and FLT3-ITD mutation in acute myeloid leukemia induction. Haematologica. 2014; 99:xxx
doi:10.3324/haematol.2013.100917

Publisher's Disclaimer.
E-publishing ahead of print is increasingly important for the rapid dissemination of science. Haematologica is, therefore, E-publishing PDF files of an early version of manuscripts that have completed a regular peer review and have been accepted for publication. E-publishing of this PDF file has been approved by the authors. After having E-published Ahead of Print, manuscripts will then undergo technical and English editing, typesetting, proof correction and be presented for the authors' final approval; the final version of the manuscript will then appear in print on a regular issue of the journal. All legal disclaimers that apply to the journal also pertain to this production process.
Potent cooperation between the NUP98-NSD1 fusion and the FLT3-ITD mutation in acute myeloid leukemia induction

Angeliki Thanasopoulou¹, Alexandar Tzankov² and Juerg Schwaller¹

¹Department of Biomedicine, University Children’s Hospital of Basel (UKBB); ²Institute for Pathology, University Hospital Basel, Switzerland

Running title: Cooperation between NUP98-NSD1 and FLT3-ITD in AML

Correspondence:
Juerg Schwaller MD, University Children’s Hospital (UKBB) Department of Biomedicine Hebelstrasse 20 CH-4031 Basel, Switzerland. E-mail: j.schwaller@unibas.ch

Acknowledgments
The authors would like to thank Radek Skoda for critically reading the manuscript. We also thank Sabine Juge and Ueli Schneider for technical support.

Funding
This work was supported by the Swiss National Science Foundation (SNF-31003A-130661/1), the Swiss Cancer League (OCS 2357-02-2009), and the Swiss Bridge Foundation. J.S. was supported by the Gertrude Von Meissner Foundation Basel.
Abstract

The NUP98-NSD1 fusion, product of the t(5;11)(q35;p15.5) chromosomal translocation, is one of the most prevalent genetic alterations in cytogenetically normal paediatric acute myeloid leukaemias and is associated with poor prognosis. Co-existence of a FLT3-ITD activating mutation has been found in more than 70% of NUP98-NSD1-positive patients. To address functional synergism we determined the transforming potential of retrovirally expressed NUP98-NSD1 and FLT3-ITD in the mouse. Expression of NUP98-NSD1 provided, mouse strain-dependent, aberrant self-renewal potential to bone marrow progenitor cells. Co-expression of FLT3-ITD increased proliferation and maintained self-renewal in vitro. Transplantation of immortalized progenitors co-expressing NUP98-NSD1 and FLT3-ITD into mice resulted in acute myeloid leukaemia after a short latency. In contrast, neither NUP98-NSD1 nor FLT3-ITD single transduced cells were able to initiate leukaemia. Interestingly, as reported for patients carrying NUP98-NSD1, an increased Flt3-ITD to wild type Flt3 mRNA expression ratio with increased Flt3-signalling was associated with rapidly induced disease. In contrast, the expression levels of the NUP98-NSD1 fusion or its proposed targets HoxA5, HoxA7, HoxA9 or HoxA10 did not differ between animals with different latencies to develop disease. Finally, leukaemic cells co-expressing NUP98-NSD1 and FLT3-ITD were very sensitive to a small molecule FLT3 inhibitor, which underlines the significance of aberrant FLT3 signalling for NUP98-NSD1-positive leukaemias and suggests new therapeutic approaches that could potentially improve the outcome of patients.
Introduction

Acute myeloid leukaemia (AML) is a heterogeneous group of myeloid malignancies that are driven by a variety of genetic alterations, which target signalling mediators, transcriptional regulators, as well as genes involved in mRNA processing or chromatin organization.\textsuperscript{1-3}

Internal tandem duplications (ITD) in the cytoplasmic domain of FLT3 that lead to constitutive kinase activation, are found in up to 20% of AMLs and are generally associated with elevated white blood cell counts and overall poor prognosis.\textsuperscript{4-6} Clinical observations and experimental studies have shown that FLT3-ITD can cooperate strongly in leukaemia induction with a variety of leukaemia-initiating gene fusions such as MLL-AF9, MLL-GAS7, AML1-ETO, PML-RARα or NUP98-HOXD13.\textsuperscript{7-13} Several studies have shown that FLT3-ITD alone can cause a myeloproliferative disorder in mice, but is not sufficient to induce AML.\textsuperscript{14-16}

NUP98-NSD1 is the product of a cytogenetically silent chromosomal translocation t(5;11) (q35;p15.5) that generates a fusion between the N-terminus of nucleoporin 98 (NUP98) and the C-terminal part of the nuclear receptor-binding SET-domain-containing protein NSD1. NUP98-NSD1 is the most frequent gene fusion in cytogenetically normal (CN) paediatric AML, and is generally associated with an aggressive disease and poor prognosis.\textsuperscript{19} In adult AML patients, NUP98-NSD1 is rarely detected, but, if present, also confers a poor AML outcome.\textsuperscript{20,21} Interestingly, several reports have shown that the vast majority of NUP98-NSD1 positive patients also bear a FLT3-ITD mutation suggesting functional cooperation.\textsuperscript{19-22} Previous work has shown that retroviral overexpression of NUP98-NSD1 alone is able to induce an AML-like disease in mice after a latency of several months.\textsuperscript{23} Here we provide experimental evidence for a potent cooperation between the NUP98-NSD1 fusion and the FLT3-ITD mutation for the transformation of murine hematopoietic cells \textit{in vitro} and \textit{in vivo}. 
Methods

Retroviral expression vectors: The pMSCV-NUP98-NSD1-neo and pMSCV-FLT3-ITD-IRES-EGFP retroviral expression vectors were kindly provided by Mark Kamps (San Diego, USA) and Justus Duyster (Freiburg, Germany) and described previously.\textsuperscript{15,23}

In vitro transduction, proliferation and immortalization assays: \(1.5 \times 10^5\) lineage-surface marker negative (Lin\textsuperscript{−}) bone marrow cells (MagCellect Kit, R&D systems, Minneapolis, USA) from 6-10 week old Balb/C or C57BL/6 mice were transduced with retrovirus on a 48-well fibronectin-coated plate according to the manufacturer’s protocol (Retronectin\textsuperscript{TM}, TaKaRa, Bio Inc., Shiga, Japan). The cells were selected with neomycin (0.8mg/ml, Life Technologies, Paisley, UK) and cultured in medium containing murine stem cell factor (mSCF), FLT3 ligand, IL-11, thrombopoietin (PeproTech, Rocky Hill, NJ). Growth in liquid culture was monitored for 7 days by counting using dead exclusion dye, trypan blue (Life Technologies, Paisley, UK) in medium (RPMI 1640, 10% FBS) containing growth factors. The PKC-412 (Midostaurin) FLT3 inhibitor was purchased from Sigma-Aldrich (M1323, St Louis, USA). Transduced progenitors were plated in methylcellulose containing IL-3, IL-6 and mSCF (M3534, Stem cell technologies, Vancouver, Canada) and colonies were counted after 7 days.

In vivo leukaemogenesis study: \(3.5 \times 10^5\) in vitro expanded cells (expressing NUP98-NSD1, FLT3-ITD, or both) were injected into sub-lethally irradiated syngeneic Balb/C mice (1x500rad) by tail vein injection. All experiments were done according to Swiss laws for animal welfare and approved by the Swiss Cantonal Veterinary Office of Basel-Stadt.

Quantitative RT-PCR: Total RNA was extracted using the RNA extraction kit (Macherey-Nagel, GmbH & Co, Duren, Germany) according to the manufacturer’s protocol. cDNA synthesis was carried out using the high capacity cDNA reverse transcription kit (Applied Biosystems, Foster City, CA, USA). mRNA expression was assessed by quantitative real-time PCR using SYBR Green on an ABI prism 7500
Sequence Detection System (Applied Biosystems). Results were normalized to \textit{Gapdh} expression.

\textbf{Retroviral integration cloning:} Splinkerette-based PCR was performed as previously described.\textsuperscript{24} PCR amplicons were separated on a 2\% agarose gel, purified and cloned into \textit{pCR2.1-TOPO} (Invitrogen) and sequenced. The obtained sequences were analysed using BLAST (NCBI).

\textbf{Flow cytometry:} For the immunophenotyping the surface markers of the bone marrow cells, the following antibodies were used: c-Kit-PE-Cy7, Mac-1-APC, FcγRII/III-PE (eBioscience, San Diego, USA) CD45R-B220-APC, Gr-1-APC-Cy7 (BD Biosciences), CD34-PE-Cy5 (Biolegend, San Diego, USA). For phospho-flow analysis, the cells were fixed (1.5\% paraformaldehyde (PFA), 10 min), permeabilised with 100\% ice-cold methanol and incubated with phospho-specific antibodies (pFLT3 (9351), pSTAT5 (3461), Cell signaling, Danvers, USA) followed by a secondary anti-rabbit, Alexa Fluor 405 labelled antibody (Life Technologies, Oregon, USA) The samples were run on a Cyan-ADP-Flow Cytometer (Dako Cytomation, Glostrup, Denmark) using Summit software (Summit Software Solutions Inc., Poway, CA, USA). The data was analysed using FlowJo (Tree Star Inc., Ashland, OR, USA).

\textbf{Microscopy:} Colonies were observed with an Olympus IX50 and cytopsin preparations and histopathological sections were observed with an Olympus BX61 using the Cell Sens software (Olympus).

\textbf{Statistics analyses:} Statistical significance among groups was determined by t test (2-tailed, unpaired/unequal variances). Comparisons of survival curves were conducted with the log-rank test using prism software 5.0 (GraphPad Software, La Jolla California USA).
**Results**

To study the cooperation between NUP98-NSD1 and FLT3-ITD we transduced bone marrow stem and progenitor cells from two different mouse strains (Balb/C, C57BL/6) with retroviruses expressing NUP98-NSD1 or FLT3-ITD alone or together [Figure 1A]. Cells transduced with NUP98-NSD1 underwent antibiotic selection for 7 days and the expression of both transgenes was determined by RT-PCR (data not shown). Serial plating in methylcellulose showed that expression of NUP98-NSD1 alone increased the self-renewal capacity of Balb/C-derived cells [Figure 1B, top panel]. In contrast, expression of NUP98-NSD1 did not increase colony formation of C57BL/6-derived cells [Figure 1B, bottom panel]. FLT3-ITD expression resulted in only limited replating activity of the cells of both strains. However, co-expression of NUP98-NSD1 and FLT3-ITD allowed serial plating of the cells. In addition, co-expression of NUP98-NSD1 and FLT3-ITD also resulted in significantly increased rates of proliferation of cells of both strains in liquid cultures [Figure 1C]. Balb/C-derived progenitors solely transduced with the NUP98-NSD1 expressing virus formed dense colonies. Cytospin preparations revealed an immature blast-like morphology, whereas NUP98-NSD1 and FLT3-ITD co-expressing cells appeared slightly more differentiated [Figure 2A]. In contrast, C57BL/6-derived cells expressing solely NUP98-NSD1 or FLT3-ITD completely lost their capacity of forming colonies and were differentiating towards mast cells and macrophages [Figure 2B]. Cells that co-expressed NUP98-NSD1 and FLT3-ITD formed dense colonies containing cells with a blast-like morphology [Figure 2B]. Immunophenotyping of Balb/C-derived cells showed that cells expressing solely NUP98-NSD1 exhibited high levels of the stem cell associated surface marker c-kit, the early myeloid FcγRII/III, but only low levels of the myelomonocytic differentiation markers Gr-1 and Mac-1 [Figure 2C, left panel]. Co-expression of FLT3-ITD resulted in lower expression of c-kit and higher expression of FcγRII/III, Gr-1 and Mac-1 [Figure 2C, middle panel]. In contrast, cells expressing only FLT3-ITD exhibited a more differentiated myeloid phenotype with high levels of Gr-1 and Mac-1 and lower levels of c-kit [Figure 2C, right panel]. In summary, this data shows that co-expression of NUP98-NSD1 with FLT3-ITD increased proliferation and the clonogenic activity of murine bone marrow cells *in vitro*. Unlike C57BL/6,
Balb/C-derived bone marrow cells expressing solely NUP98-NSD1 could be serially replated.

We next addressed a potential functional cooperation between NUP98-NSD1 and FLT3-ITD in vivo. For the in vivo experiments we chose two independently generated sets of cell populations expressing NUP98-NSD1, FLT3-ITD or both that we had analysed in vitro. We focused on Balb/C-derived cells, as they were immortalized in vitro by NUP98-NSD1 alone and in combination with FLT3-ITD. We harvested bone marrow progenitor cells from methylcellulose cultures after 2 platings and transplanted them into sub-lethally irradiated syngeneic mice [Figure 1A]. As shown in Figure 3A, all mice that received NUP98-NSD1 and FLT3-ITD co-expressing cells, rapidly developed AML that was fully transplantable into secondary recipients [Figure S1]. The diseased mice exhibited enlarged spleens and significantly increased circulating white blood counts [Figure 3B]. Histopathology showed widespread infiltration of the bone marrow, spleen and multiple solid organs [Figure 3C] with leukaemic blasts that displayed myeloid surface antigens (Mac-1+/Gr-1+/FcγRII/IIIb/c-kit+/CD34-) [Figure 3D]. In contrast, mice transplanted with cells expressing NUP98-NSD1 alone developed some signs of distress after a significantly longer latency [Figure 3A]. Histopathology of these mice showed increased number of myeloid cells in the bone marrow and spleen [Figure 4A]. The majority of the mice showed a mildly increased number of circulating neutrophils [Figure S1C]. Flow cytometry revealed an expansion of Mac-1+/Gr-1+ positive cells in the bone marrow, compatible with a phenotype of myeloid hyperplasia [Figure 4B]. Mice receiving FLT3-ITD-only-expressing cells did not show any signs of disease over several months post-transplant.

Two independent experiments resulted in different latency periods to develop the disease of mice transplanted with NUP98-NSD1 and FLT3-ITD co-expressing progenitors (12 days in experiment “A” versus 91 days in experiment “B”) [Figure 3A]. To explore the clonal composition we compared the viral integration pattern of the cells harvested from the methylcellulose cultures before transplant and the resulting AMLs of both experiments. As shown in Figure S2, splinkerette-PCR revealed overlapping integration pattern after in vitro immortalization and the
developing AML. Two viral integrations could be determined in experiment A and one in experiment B. These observations suggest *in vivo* expansion of an *in vitro* preselected clone. We also compared the expression levels of the HoxA gene cluster previously associated with transformation by NUP98-NSD1. As shown in Figure 5A, we observed significant increased levels of HoxA5, HoxA7, HoxA9 and HoxA10 RNA expression in the leukaemic cells, however there was no significant difference between both experiments. In addition, the expression levels of the NUP98-NSD1 fusion mRNA in the leukaemic blasts did not differ between both experiments.

In contrast, we observed that the different latency periods in experiments A and B correlated with an increased expression ratio of mutated Flt3-ITD to wild type Flt3 mRNA. Higher Flt3-ITD mRNA expression levels were associated with a significantly shorter latency [Figure 5B]. To address whether these changes might translate into different activation levels of FLT3-derived cellular signals we performed phospho-flow analysis. As shown in Figure 5C, cells from experiment A after *in vitro* immortalization as well as upon AML formation *in vivo*, exhibited higher levels of pFLT3 than cells from experiment B. Similarly, although less pronounced, we observed a moderate increase in the basal pSTAT5 levels in cells from experiment A. Collectively these observations suggest that the shorter latency of experiment A is the consequence of a stronger activation of FLT3-ITD- rather than NUP98-NSD1-mediated cellular signals.

Selective small-molecule-inhibitors of FLT3 are currently being evaluated in clinical AML trials. We therefore also assessed the sensitivity of *in vitro* immortalized progenitors expressing NUP98-NSD1 or NUP98-NSD1 and FLT3-ITD to increasing doses of a FLT3 inhibitor (PKC-412, Midostaurin). As shown in Figure 5D, cells co-expressing NUP98-NSD1 and FLT3-ITD were significantly more sensitive to PKC-412 treatment than cells immortalized by NUP98-NSD1 alone. Likewise, cells immortalized by co-expression of the MLL-AF9 fusion with FLT3-ITD were more sensitive to PKC-412 than cells immortalized by MLL-AF9 or normal lineage marker-depleted mouse bone marrow cells.

Taken together, these results demonstrate a potent cooperation between NUP98-NSD1 and FLT3-ITD in leukaemic transformation *in vitro* and *in vivo* and revealed that
expansion of NUP98-NSD1 and FLT3-ITD co-expressing cells significantly depends on FLT3-derived signals.
Discussion

Previous studies demonstrated that the vast majority of the NUP98-NSD1 positive AML patients also carry an activating FLT3-ITD mutation indicating functional cooperation. In the present study, we provide experimental evidence that co-expression of NUP98-NSD1 and FLT3-ITD cooperate for transformation in vitro and the development of AML in vivo. In contrast, neither NUP98-NSD1 nor FLT3-ITD expression was able to induce the disease.

Previous work has suggested that retroviral overexpression of the NUP98-NSD1 fusion in murine bone marrow cells could result in an AML-like disease in mice. The reasons for the discrepancy with our observations are not fully clear, but could be based on different protocols of retroviral production and transduction, or genetic differences of the used mouse strains. Interestingly, we observed in several independent experiments that expression of NUP98-NSD1 provided in vitro self-renewal capacity to Balb/C but not to C57BL/6-derived bone marrow cells. Co-expression of NUP98-NSD1 with FLT3-ITD was able to immortalize cells from both strains [Figure 1]. Several previous studies have clearly demonstrated that Balb/C mice are more prone for transformation of haematopoietic cells but the underlying mechanism is poorly understood. The observed strain-dependent differences of NUP8-NSD1 in haematopoietic cells suggest that Balb/C-derived cells might carry alterations that are functionally linked to NUP98-NSD1 induced transformation in vitro.

In two independent experiments, we observed that mice transplanted with NUP98-NSD1 immortalized cells developed myeloid hyperplasia in the bone marrow and spleen, associated with increased neutrophil counts in the majority of the mice. The discrepancy for our results to Wang et al. might also result from a different experimental setup: we transplanted in vitro immortalized and expanded bone marrow progenitor cells following a protocol previously established for the in vivo transforming potential of MLL-fusions. Nevertheless, retroviral overexpression of the NUP98-HOXA9 fusion has been previously shown also to first induce a chronic
myeloproliferative disorder with progression to AML after a long latency.\textsuperscript{30} The observed generally long latency periods for AML development in mice upon transplanting cells overexpressing different NUP98 fusions support the idea of a general indispensable acquisition of secondary mutations such as e.g. FLT3-ITD.\textsuperscript{31}

We and others have previously shown that transplantation of retroviral FLT3-ITD expressing progenitors can cause a myeloproliferative disease \textit{in vivo}.\textsuperscript{14,15} In contrast to those experiments, we here transplanted \textit{in vitro} selected and expanded progenitors. As shown in Figures 1B & 2, expression of FLT3-ITD alone resulted in a poor self-renewal capacity and was associated with differentiation of bone marrow progenitors towards monocytes/macrophages and mast cells, which most probably abrogated their leukaemogenic potential \textit{in vivo}.

Interestingly, expression of FLT3-ITD with NUP98-NSD1 not only led to AML after short latency \textit{in vivo}, but also influenced the immunophenotype of the \textit{in vitro} transformed cells as seen by reduced c-kit and increased Mac-1, Gr-1 expression. Similar observations have been made upon co-expression of FLT3-ITD with the PML-RAR\textsubscript{α} or MLL-AF9 fusions.\textsuperscript{7,13}

Additionally, we found that the length of the latency period for AML induction by co-expression of NUP98-NSD1 and FLT3-ITD correlated with the ratio of \textit{FLT3-ITD} to wild type \textit{Flt3} mRNA expression [Figure 5B]. Phospho-flow experiments suggested that increased FLT3-ITD expression resulted in increased FLT3-derived cellular signals [Figure 5C]. Interestingly, our observations in the mouse closely phenocopied recent observations demonstrating that the prognosis of AML patients with NUP98-NSD1 could be correlated to a high \textit{Flt3-ITD}/wild type \textit{Flt3} mRNA expression ratio.\textsuperscript{25}

The reasons for different FLT3-ITD expression levels remain unclear but could be influenced by the type of haematopoietic stem- and or progenitor cell targeted by the two viruses, as well as different retroviral integration sites. As shown in Figure S2 we found an overlapping pattern of retroviral integrations before transplant and in resulting cells from the induced AML suggesting \textit{in vivo} expansion of a preselected clone. Two integration sites (in chromosomes 7 and 12) and one (chromosome 15) could be identified in experiments A and B respectively. These different integration
events could theoretically not only provide clonal advantage, but also result in different expression levels of the viral encoded transgenes.\textsuperscript{24} However, in contrast to FLT3-ITD, we found no significantly different expression levels of the NUP98-NSD1 fusion or its proposed downstream target the HoxA gene cluster (HoxA5, HoxA7, HoxA9, HoxA10) in cells from both experiments [Figure 5A].

Similar to what has been previously shown for AML co-expressing FLT3-ITD with MLL-AF9, AML1-ETO or NUP98-HOXD13, leukaemic blasts expressing NUP98-NSD1 and FLT3-ITD were very sensitive to treatment with a small-molecule-inhibitor of FLT3 [Figure 5D]. This observation further supports the importance of the FLT3-mediated cellular signalling in the development of the disease and urges to explore selective new generation FLT3 inhibitors for patients with aggressive AML carrying NUP98-NSD1 and FLT3-ITD.

**Authorship and Disclosures**

A.T. designed and performed experiments, analysed data and wrote the paper, A.Tz. performed experiments and analysed data, J.S. designed and performed experiments, analysed data and wrote the paper.
References

13. Tam WF, Hähnel PS, Schüler A, Lee BH, Okabe R, Zhu N, et al. STAT5 is crucial to maintain leukemic stem cells in acute myelogenous
mutation identifies a prognostically relevant subgroup of paediatric acute myeloid leukemia patients suitable for monitoring by real time quantitative PCR. Genes Chromosomes Cancer. 2013 52(11):1053-64
Figure Legends

Figure 1: Functional cooperation of NUP98-NSD1 and FLT3-ITD in vitro

(A) Schematic outline of the experimental strategy to address the functional cooperation between NUP98-NSD1 and FLT3-ITD.

(B) Serial plating in methylcellulose of cells expressing NUP98-NSD1, FLT3-ITD or both, of Balb/C (upper panel) and C57BL/6 mice (lower panel): NUP98-NSD1 increased colony formation of Balb/C- but not of C57BL/6-derived cells, whereas co-expression of FLT3-ITD supported colony formation in both strains. No significant replating activity was observed upon expression of FLT3-ITD or the control vector (GFP) in cells of both strains.

(C) Proliferation of cells expressing NUP98-NSD1, FLT3-ITD or both in liquid culture. Co-expression of NUP98-NSD1 and FLT3-ITD significantly increased proliferation compared to single transduced cells. Proliferation was assessed in triplicates using trypan blue staining. Error bars represent the standard deviations from five independent experiments with Balb/C and three independent experiments with C57BL/6-derived cells (t-test, 2-tailed, unpaired/unequal variances, *, p ≤ 0.05, **, p≤0.01).

Figure 2: Phenotypic analysis of NUP98-NSD1 and FLT3-ITD expressing progenitors

(A & B) Photomicrographs (x100) of cytospots of cells and their colonies (smaller picture, x4) formed in methylcellulose cultures of Balb/C (A) and of C57BL/6 (B) - derived cells. NUP98-NSD1 expressing Balb/C progenitors formed dense colonies and exhibited a blast-like morphology. NUP98-NSD1 + FLT3-ITD co-expressing cells formed less dense colonies and had a more differentiated phenotype, whereas FLT3-ITD-only-expressing progenitors differentiated into mast cells and macrophages. C57BL/6-derived cells co-expressing NUP98-NSD1 + FLT3-ITD formed dense colonies and exhibited a blast-like morphology. Cells expressing only NUP98-NSD1 or FLT3-ITD differentiated into mast cells and macrophages.

(C) Flow cytometry revealed that NUP98-NSD1 expressing cells were c-kit+, FcγRII/III+, Mac-1b, Gr-1b. Co-expression of FLT3-ITD resulted in lower c-kit and higher FcγRII/III, Gr-1 and Mac-1 expression. FLT3-ITD single transduced cells were c-kitb, FcγRII/III+, Gr-1+, Mac-1+.
Figure 3: Functional cooperation of NUP98-NSD1 and FLT3-ITD in vivo

(A) Kaplan-Meier survival plot of mice transplanted with cells expressing NUP98-NSD1, NUP98-NSD1 + FLT3-ITD, or solely FLT3-ITD harvested after two rounds of plating in methylcellulose and expanded in liquid culture. Transplantation of cells co-expressing NUP98-NSD1 + FLT3-ITD resulted in AML after a median latency of 12 days (experiment “A”), and 91 days (experiment “B”). Mice receiving cells expressing only NUP98-NSD1 developed some signs of disease after a median latency of 334 days.

(B) Diseased mice transplanted with cells co-expressing NUP98-NSD1 + FLT3-ITD showed significantly increased spleen weights and peripheral white blood cell counts. Error bars represent the standard deviation of 5 mice per group (t-test, 2-tailed, unpaired/unequal variances, *, p ≤ 0.05, **, p ≤ 0.01).

(C) Representative images of peripheral blood smears stained with Wright-Giemsa (x60) (i), histopathological sections of bone marrow (x20) (ii), spleen (x10) (iii), and liver (x10) (iv) of diseased mice transplanted with NUP98-NSD1 + FLT3-ITD co-expressing cells. Leukaemic blasts were found in the peripheral blood and extensively infiltrated the bone marrow, spleen and liver.

(D) Leukaemic blasts from mice transplanted with NUP98-NSD1 + FLT3-ITD transduced cells exhibited a myeloid phenotype, expressing Mac-1⁺, Gr-1⁺, FcγRII/III⁺, CD34⁻, c-kit⁻ as assessed by flow cytometry.

Figure 4: Mice transplanted with NUP98-NSD1 expressing progenitors develop myeloid hyperplasia

(A) Representative images of Wright-Giemsa stained peripheral blood smears (x60) (i), and histopathological sections of bone marrow (x20) (ii), spleen (x10) (iii) and liver (x10) (iv) of diseased mice transplanted with cells expressing only NUP98-NSD1. Histopathology revealed expansion of differentiating myeloid elements in the bone marrow and the spleen.

(B) Mice transplanted with cells expressing only NUP98-NSD1 showed significant expansion of the myeloid bone marrow compartment (Mac-1⁺, Gr-1⁺) as assessed by flow cytometry compared to same aged control mice (t-test, 2-tailed,
unpaired/unequal variances, p=0.0043). The flow cytometry panel is representative for 5 transplanted mice compared to age-matched controls.

**Figure 5: Increased FLT3-signalling in short-latency AML cells and sensitivity to a FLT3 inhibitor**

(A) NUP98-NSD1 + FLT3-ITD expressing leukemic blasts from experiments [A] and [B] expressed significantly increased levels of \( \text{HoxA5, HoxA7, HoxA9 and HoxA10 mRNA} \) levels compared to lineage negative bone marrow cells. The expression of the NUP98-NSD1 was not different between experiments. Error bars represent the standard deviations from two experiments run in duplicates (t-test, 2-tailed, unpaired/unequal variances, *, p ≤ 0.05).

(B) NUP98-NSD1 + FLT3-ITD expressing leukemic blasts from transplanted mice express significantly different \( \text{Flt3-ITD/wild type Flt3 mRNA} \) levels between experiment [A] and experiment [B] as detected by Q-PCR (p=0.003). A higher \( \text{Flt3-ITD/wild type Flt3 mRNA ratio} \) correlated with a shorter latency. The error bars indicate the standard deviation out of 5 analysed mice per group in duplicates (t-test, 2-tailed, unpaired/unequal variances, *, p ≤ 0.05).

(C) Phospho-flow cytometric analysis for pFLT3 revealed that cells from experiment [A] express more pFLT3 than cells from experiment [B] both after *in vitro* immortalization and after *in vivo* AML induction. Similar results were found for pSTAT5. Graphs in the lower panel summarize the median fluorescence intensity obtained in 3 independent experiments.

(D) Immortalized NUP98-NSD1 + FLT3-ITD co-expressing (Balb/C-derived) bone marrow progenitors are more sensitive to the PKC-412 small molecule FLT3 inhibitor than cells immortalized by NUP98-NSD1, MLL-AF9 fusion, or normal bone marrow cells. The graph represents survival of the cells after a 24-hour-exposure to different doses of PKC-412 as assessed by a WST-1 assay performed in quadruplicates (t-test, 2-tailed, unpaired/unequal variances, ****, p ≤ 0.0001).
Figure 1 Thanasopoulou et al.,

A) Schematic representation of the experimental setup:

- Donor mouse
- Lin(-) BM cells
- Methylcellulose CFU-GM
- Expansion
- Receptor mouse (Sublethally Irradiated)

B) Graph showing the number of colonies over different platings:

- NUP98-NSD1
- NUP98-NSD1 + FLT3-ITD
- FLT3-ITD
- GFP

C) Graph showing the number of cells over different days:

- NUP98-NSD1 + FLT3-ITD
- NUP98-NSD1
- FLT3-ITD

** indicates statistical significance.
Figure 5 Thanasopoulou et al.,

(A) mRNA expression (1/ΔCt)

- Exp. [A]
- Exp. [B]
- LIN(-) BONE MARROW

(HOXA5, HOXA7, HOXA9, HOXA10, NUP98-NSD1)

(B) Flt3-ITD/Flt3 mRNA

- Exp. [A]
- Exp. [B]

(C) In vitro vs In vivo

- pFLT3 (MFI)
- pSTAT5 (MFI)

(D) Survival (%)

- MLL-AF9 + FLT3-ITD
- NUP98-NSD1
- NUP98-NSD1 + FLT3-ITD
- LIN(-) BONE MARROW
- MLL-AF9

PKC-412 (μM)

0.1 0.3 0.5 1 3 5
Supplementary figure legend

Figure S1:
(A) Transplantation of NUP98-NSD1 + FLT3-ITD induced AML into secondary recipients. Total bone marrow cells of diseased mice transplanted with NUP98-NSD1 + FLT3-ITD immortalized cells from experiment [A] were injected into sub-lethally irradiated syngenic recipients. All mice developed AML with a median latency of 35 days (Kaplan Meier survival plot).
(B) Representative images of histopathology sections of bone marrow (x20) (i), spleen (x20) (ii), liver (x20) (iii) and lung (x20) (iv) of diseased mice showed extensive multi-organ infiltration by leukaemic blasts.
(C) Blood analysis of diseased mice transplanted with NUP98-NSD1 expressing cells. Haemoglobin levels, the number of platelets, and the WBC remained in the normal range but the number of neutrophils was increased. The grey zone corresponds to normal values.

Figure S2:
(A) Gel picture of the splinkerette-PCR revealed overlapping viral integration pattern between in vitro immortalized cells and the resulting AMLs. When indicated, DNA bands were sequenced in experiment A could be determined two integration sites and one in experiment B. The second integration site found in experiment B, corresponding to the lower band, was too small to specifically locate it in the genome.
(B) Genomic integration sites in cells from Experiment A and B
A

<table>
<thead>
<tr>
<th>Exp. A</th>
<th>In vitro: replating</th>
<th>In vivo: AML</th>
</tr>
</thead>
<tbody>
<tr>
<td>194</td>
<td>chr.7</td>
<td></td>
</tr>
<tr>
<td>114</td>
<td>chr.12</td>
<td></td>
</tr>
</tbody>
</table>

B

<table>
<thead>
<tr>
<th>Transplant Experiments</th>
<th>Gene Name</th>
<th>Full Name</th>
<th>Chromosome in mouse</th>
<th>Location and distance for retroviral integration</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>Tao2k</td>
<td>serine/threonine-protein kinase TAO2 isoform 2</td>
<td>7</td>
<td>4729 bp at 5' side</td>
</tr>
<tr>
<td>A</td>
<td>Ilgf</td>
<td>insulin-like growth factor-binding protein 3 receptor</td>
<td>7</td>
<td>3490 bp at 3' side</td>
</tr>
<tr>
<td>A</td>
<td>Atxn7I1</td>
<td>ataxin-7-like protein 1 isoform2</td>
<td>12</td>
<td>62070 bp at 5' side</td>
</tr>
<tr>
<td>A</td>
<td>Atxn7I2</td>
<td>ataxin-7-like protein 1 isoform 1</td>
<td>12</td>
<td>214220 bp at 3' side</td>
</tr>
<tr>
<td>B</td>
<td>Kanl2</td>
<td>KAT8 regulatory NSI complex subunit 2</td>
<td>15</td>
<td>Insertion after the 1048 nucleotide</td>
</tr>
</tbody>
</table>